Neuronetics (STIM) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results
March 7, 2023 7:30 AM ESTMALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2022.
Fourth Quarter 2022 Highlights
Fourth quarter 2022 revenue of $18.2 million, representing a 21% increase as compared to the fourth quarter 2021Achieved record U.S. treatment session revenue of $12.5 million in the fourth quarter... More